Recorded sales improved to SEK 17.9m (10.9m in Q4 and SEK 0m in Q1 2023), and the cash balance was SEK 39.9m (27.2m). The main difference is the support from recurring services related to VADA and the VRK1 program. Spring BioScience continues to market and negotiate with new potential partners for the DISA, NIMA and NASH programs, where the DISA program has attracted interest at the recent conference “Immuno-Oncology Summit Europe 2024”. Our Base Case ahead of Q1 was SEK 2.90 (Bull SEK 8.6 and Bear SEK 0.50).

https://www.redeye.se/research/1005150/sprint-bioscience-q1-improved-sales-and-activity?utm_source=finwire&utm_medium=RSS

Redeye